Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Discovery of a CD10-negative B-progenitor in human fetal life identifies unique ontogeny-related developmental programs.

O'Byrne S, Elliott N, Rice S, Buck G, Fordham N, Garnett C, Godfrey L, Crump NT, Wright G, Inglott S, Hua P, Psaila B, Povinelli B, Knapp DJHF, Agraz-Doblas A, Bueno C, Varela I, Bennett P, Koohy H, Watt SM, Karadimitris A, Mead AJ, Ancliff P, Vyas P, Menendez P, Milne TA, Roberts I, Roy A.

Blood. 2019 Sep 26;134(13):1059-1071. doi: 10.1182/blood.2019001289. Epub 2019 Aug 5.

PMID:
31383639
2.

DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation.

Godfrey L, Crump NT, Thorne R, Lau IJ, Repapi E, Dimou D, Smith AL, Harman JR, Telenius JM, Oudelaar AM, Downes DJ, Vyas P, Hughes JR, Milne TA.

Nat Commun. 2019 Jun 26;10(1):2803. doi: 10.1038/s41467-019-10844-3.

3.

Addendum: Precise tuning of gene expression levels in mammalian cells.

Michaels YS, Barnkob MB, Barbosa H, Baeumler TA, Thompson MK, Andre V, Colin-York H, Fritzsche M, Gileadi U, Sheppard HM, Knapp DJHF, Milne TA, Cerundolo V, Fulga TA.

Nat Commun. 2019 Jun 10;10(1):2622. doi: 10.1038/s41467-019-10615-0.

4.

Why are so many MLL lysine methyltransferases required for normal mammalian development?

Crump NT, Milne TA.

Cell Mol Life Sci. 2019 Aug;76(15):2885-2898. doi: 10.1007/s00018-019-03143-z. Epub 2019 May 16. Review.

5.

Decoupling tRNA promoter and processing activities enables specific Pol-II Cas9 guide RNA expression.

Knapp DJHF, Michaels YS, Jamilly M, Ferry QRV, Barbosa H, Milne TA, Fulga TA.

Nat Commun. 2019 Apr 2;10(1):1490. doi: 10.1038/s41467-019-09148-3.

6.

Precise tuning of gene expression levels in mammalian cells.

Michaels YS, Barnkob MB, Barbosa H, Baeumler TA, Thompson MK, Andre V, Colin-York H, Fritzsche M, Gileadi U, Sheppard HM, Knapp DJHF, Milne TA, Cerundolo V, Fulga TA.

Nat Commun. 2019 Feb 18;10(1):818. doi: 10.1038/s41467-019-08777-y.

7.

Author Correction: Metabolic gatekeeper function of B-lymphoid transcription factors.

Chan LN, Chen Z, Braas D, Lee JW, Xiao G, Geng H, Cosgun KN, Hurtz C, Shojaee S, Cazzaniga V, Schjerven H, Ernst T, Hochhaus A, Kornblau SM, Konopleva M, Pufall MA, Cazzaniga G, Liu GJ, Milne TA, Koeffler HP, Ross TS, Sánchez-García I, Borkhardt A, Yamamoto KR, Dickins RA, Graeber TG, Müschen M.

Nature. 2018 Jun;558(7711):E5. doi: 10.1038/s41586-018-0164-5.

8.

The basic helix-loop-helix transcription factor SHARP1 is an oncogenic driver in MLL-AF6 acute myelogenous leukemia.

Numata A, Kwok HS, Kawasaki A, Li J, Zhou QL, Kerry J, Benoukraf T, Bararia D, Li F, Ballabio E, Tapia M, Deshpande AJ, Welner RS, Delwel R, Yang H, Milne TA, Taneja R, Tenen DG.

Nat Commun. 2018 Apr 24;9(1):1622. doi: 10.1038/s41467-018-03854-0.

9.

Ezh2 and Runx1 Mutations Collaborate to Initiate Lympho-Myeloid Leukemia in Early Thymic Progenitors.

Booth CAG, Barkas N, Neo WH, Boukarabila H, Soilleux EJ, Giotopoulos G, Farnoud N, Giustacchini A, Ashley N, Carrelha J, Jamieson L, Atkinson D, Bouriez-Jones T, Prinjha RK, Milne TA, Teachey DT, Papaemmanuil E, Huntly BJP, Jacobsen SEW, Mead AJ.

Cancer Cell. 2018 Feb 12;33(2):274-291.e8. doi: 10.1016/j.ccell.2018.01.006.

10.

LEDGF: a leukemia-specific target.

Milne TA.

Blood. 2018 Jan 4;131(1):4-5. doi: 10.1182/blood-2017-11-815449. No abstract available.

PMID:
29301770
11.

In situ functional dissection of RNA cis-regulatory elements by multiplex CRISPR-Cas9 genome engineering.

Wu Q, Ferry QRV, Baeumler TA, Michaels YS, Vitsios DM, Habib O, Arnold R, Jiang X, Maio S, Steinkraus BR, Tapia M, Piazza P, Xu N, Holländer GA, Milne TA, Kim JS, Enright AJ, Bassett AR, Fulga TA.

Nat Commun. 2017 Dec 13;8(1):2109. doi: 10.1038/s41467-017-00686-2.

12.

The Cks1/Cks2 axis fine-tunes Mll1 expression and is crucial for MLL-rearranged leukaemia cell viability.

Grey W, Ivey A, Milne TA, Haferlach T, Grimwade D, Uhlmann F, Voisset E, Yu V.

Biochim Biophys Acta Mol Cell Res. 2018 Jan;1865(1):105-116. doi: 10.1016/j.bbamcr.2017.09.009. Epub 2017 Sep 20.

13.

Hepcidin is regulated by promoter-associated histone acetylation and HDAC3.

Pasricha SR, Lim PJ, Duarte TL, Casu C, Oosterhuis D, Mleczko-Sanecka K, Suciu M, Da Silva AR, Al-Hourani K, Arezes J, McHugh K, Gooding S, Frost JN, Wray K, Santos A, Porto G, Repapi E, Gray N, Draper SJ, Ashley N, Soilleux E, Olinga P, Muckenthaler MU, Hughes JR, Rivella S, Milne TA, Armitage AE, Drakesmith H.

Nat Commun. 2017 Sep 1;8(1):403. doi: 10.1038/s41467-017-00500-z.

14.

Metabolic gatekeeper function of B-lymphoid transcription factors.

Chan LN, Chen Z, Braas D, Lee JW, Xiao G, Geng H, Cosgun KN, Hurtz C, Shojaee S, Cazzaniga V, Schjerven H, Ernst T, Hochhaus A, Kornblau SM, Konopleva M, Pufall MA, Cazzaniga G, Liu GJ, Milne TA, Koeffler HP, Ross TS, Sánchez-García I, Borkhardt A, Yamamoto KR, Dickins RA, Graeber TG, Müschen M.

Nature. 2017 Feb 23;542(7642):479-483. doi: 10.1038/nature21076. Epub 2017 Feb 13. Erratum in: Nature. 2018 Jun;558(7711):E5.

15.

Mouse models of MLL leukemia: recapitulating the human disease.

Milne TA.

Blood. 2017 Apr 20;129(16):2217-2223. doi: 10.1182/blood-2016-10-691428. Epub 2017 Feb 8. Review.

16.

MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia.

Kerry J, Godfrey L, Repapi E, Tapia M, Blackledge NP, Ma H, Ballabio E, O'Byrne S, Ponthan F, Heidenreich O, Roy A, Roberts I, Konopleva M, Klose RJ, Geng H, Milne TA.

Cell Rep. 2017 Jan 10;18(2):482-495. doi: 10.1016/j.celrep.2016.12.054.

17.

MLL-AF4 binds directly to a BCL-2 specific enhancer and modulates H3K27 acetylation.

Godfrey L, Kerry J, Thorne R, Repapi E, Davies JO, Tapia M, Ballabio E, Hughes JR, Geng H, Konopleva M, Milne TA.

Exp Hematol. 2017 Mar;47:64-75. doi: 10.1016/j.exphem.2016.11.003. Epub 2016 Nov 14.

18.

Instructive Role of MLL-Fusion Proteins Revealed by a Model of t(4;11) Pro-B Acute Lymphoblastic Leukemia.

Lin S, Luo RT, Ptasinska A, Kerry J, Assi SA, Wunderlich M, Imamura T, Kaberlein JJ, Rayes A, Althoff MJ, Anastasi J, O'Brien MM, Meetei AR, Milne TA, Bonifer C, Mulloy JC, Thirman MJ.

Cancer Cell. 2016 Nov 14;30(5):737-749. doi: 10.1016/j.ccell.2016.10.008.

19.

MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome.

Stavropoulou V, Kaspar S, Brault L, Sanders MA, Juge S, Morettini S, Tzankov A, Iacovino M, Lau IJ, Milne TA, Royo H, Kyba M, Valk PJM, Peters AHFM, Schwaller J.

Cancer Cell. 2016 Jul 11;30(1):43-58. doi: 10.1016/j.ccell.2016.05.011. Epub 2016 Jun 23.

20.

MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199.

Benito JM, Godfrey L, Kojima K, Hogdal L, Wunderlich M, Geng H, Marzo I, Harutyunyan KG, Golfman L, North P, Kerry J, Ballabio E, Chonghaile TN, Gonzalo O, Qiu Y, Jeremias I, Debose L, O'Brien E, Ma H, Zhou P, Jacamo R, Park E, Coombes KR, Zhang N, Thomas DA, O'Brien S, Kantarjian HM, Leverson JD, Kornblau SM, Andreeff M, Müschen M, Zweidler-McKay PA, Mulloy JC, Letai A, Milne TA, Konopleva M.

Cell Rep. 2015 Dec 29;13(12):2715-27. doi: 10.1016/j.celrep.2015.12.003. Epub 2015 Dec 17.

21.

Dangerous liaisons: cooperation between Pbx3, Meis1 and Hoxa9 in leukemia.

Thorne RM, Milne TA.

Haematologica. 2015 Jul;100(7):850-3. doi: 10.3324/haematol.2015.129932. No abstract available.

22.

Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia.

Geng H, Hurtz C, Lenz KB, Chen Z, Baumjohann D, Thompson S, Goloviznina NA, Chen WY, Huan J, LaTocha D, Ballabio E, Xiao G, Lee JW, Deucher A, Qi Z, Park E, Huang C, Nahar R, Kweon SM, Shojaee S, Chan LN, Yu J, Kornblau SM, Bijl JJ, Ye BH, Ansel KM, Paietta E, Melnick A, Hunger SP, Kurre P, Tyner JW, Loh ML, Roeder RG, Druker BJ, Burger JA, Milne TA, Chang BH, Müschen M.

Cancer Cell. 2015 Mar 9;27(3):409-25. doi: 10.1016/j.ccell.2015.02.003.

23.

MLL5 expression as a biomarker for DNA hypermethylation and sensitivity to epigenetic therapy.

Milne TA.

Haematologica. 2014 Sep;99(9):1405-7. doi: 10.3324/haematol.2014.113357. No abstract available.

24.

Epigenetic control of gene expression in leukemogenesis: Cooperation between wild type MLL and MLL fusion proteins.

Ballabio E, Milne TA.

Mol Cell Oncol. 2014 Oct 29;1(2):e955330. doi: 10.1080/23723548.2014.955330. eCollection 2014 Apr-Jun. Review.

25.

RUNX1 is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interaction.

Wilkinson AC, Ballabio E, Geng H, North P, Tapia M, Kerry J, Biswas D, Roeder RG, Allis CD, Melnick A, de Bruijn MF, Milne TA.

Cell Rep. 2013 Jan 31;3(1):116-27. doi: 10.1016/j.celrep.2012.12.016. Epub 2013 Jan 24.

26.

Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia.

Geng H, Brennan S, Milne TA, Chen WY, Li Y, Hurtz C, Kweon SM, Zickl L, Shojaee S, Neuberg D, Huang C, Biswas D, Xin Y, Racevskis J, Ketterling RP, Luger SM, Lazarus H, Tallman MS, Rowe JM, Litzow MR, Guzman ML, Allis CD, Roeder RG, Müschen M, Paietta E, Elemento O, Melnick AM.

Cancer Discov. 2012 Nov;2(11):1004-23. doi: 10.1158/2159-8290.CD-12-0208. Epub 2012 Oct 29.

27.

Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia.

Akalin A, Garrett-Bakelman FE, Kormaksson M, Busuttil J, Zhang L, Khrebtukova I, Milne TA, Huang Y, Biswas D, Hess JL, Allis CD, Roeder RG, Valk PJ, Löwenberg B, Delwel R, Fernandez HF, Paietta E, Tallman MS, Schroth GP, Mason CE, Melnick A, Figueroa ME.

PLoS Genet. 2012;8(6):e1002781. doi: 10.1371/journal.pgen.1002781. Epub 2012 Jun 21.

28.

Intragenic enhancers act as alternative promoters.

Kowalczyk MS, Hughes JR, Garrick D, Lynch MD, Sharpe JA, Sloane-Stanley JA, McGowan SJ, De Gobbi M, Hosseini M, Vernimmen D, Brown JM, Gray NE, Collavin L, Gibbons RJ, Flint J, Taylor S, Buckle VJ, Milne TA, Wood WG, Higgs DR.

Mol Cell. 2012 Feb 24;45(4):447-58. doi: 10.1016/j.molcel.2011.12.021. Epub 2012 Jan 19.

29.

Molecular and Epigenetic Mechanisms of MLL in Human Leukemogenesis.

Ballabio E, Milne TA.

Cancers (Basel). 2012 Sep 10;4(3):904-44. doi: 10.3390/cancers4030904.

30.

Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes.

Biswas D, Milne TA, Basrur V, Kim J, Elenitoba-Johnson KS, Allis CD, Roeder RG.

Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):15751-6. doi: 10.1073/pnas.1111498108. Epub 2011 Sep 6.

31.

Recognition of a mononucleosomal histone modification pattern by BPTF via multivalent interactions.

Ruthenburg AJ, Li H, Milne TA, Dewell S, McGinty RK, Yuen M, Ueberheide B, Dou Y, Muir TW, Patel DJ, Allis CD.

Cell. 2011 May 27;145(5):692-706. doi: 10.1016/j.cell.2011.03.053. Epub 2011 May 19.

32.

Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis.

Milne TA, Kim J, Wang GG, Stadler SC, Basrur V, Whitcomb SJ, Wang Z, Ruthenburg AJ, Elenitoba-Johnson KS, Roeder RG, Allis CD.

Mol Cell. 2010 Jun 25;38(6):853-63. doi: 10.1016/j.molcel.2010.05.011. Epub 2010 Jun 10.

33.

Pro isomerization in MLL1 PHD3-bromo cassette connects H3K4me readout to CyP33 and HDAC-mediated repression.

Wang Z, Song J, Milne TA, Wang GG, Li H, Allis CD, Patel DJ.

Cell. 2010 Jun 25;141(7):1183-94. doi: 10.1016/j.cell.2010.05.016. Epub 2010 Jun 10.

34.

Lens epithelium-derived growth factor fusion proteins redirect HIV-1 DNA integration.

Ferris AL, Wu X, Hughes CM, Stewart C, Smith SJ, Milne TA, Wang GG, Shun MC, Allis CD, Engelman A, Hughes SH.

Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3135-40. doi: 10.1073/pnas.0914142107. Epub 2010 Feb 1.

35.

Regulation of hippocampal H3 histone methylation by acute and chronic stress.

Hunter RG, McCarthy KJ, Milne TA, Pfaff DW, McEwen BS.

Proc Natl Acad Sci U S A. 2009 Dec 8;106(49):20912-7. doi: 10.1073/pnas.0911143106. Epub 2009 Nov 23.

36.

RAD6-Mediated transcription-coupled H2B ubiquitylation directly stimulates H3K4 methylation in human cells.

Kim J, Guermah M, McGinty RK, Lee JS, Tang Z, Milne TA, Shilatifard A, Muir TW, Roeder RG.

Cell. 2009 May 1;137(3):459-71. doi: 10.1016/j.cell.2009.02.027.

37.

Chromatin immunoprecipitation (ChIP) for analysis of histone modifications and chromatin-associated proteins.

Milne TA, Zhao K, Hess JL.

Methods Mol Biol. 2009;538:409-23. doi: 10.1007/978-1-59745-418-6_21.

38.

Interaction of MLL amino terminal sequences with menin is required for transformation.

Caslini C, Yang Z, El-Osta M, Milne TA, Slany RK, Hess JL.

Cancer Res. 2007 Aug 1;67(15):7275-83.

39.

Regulation of MLL1 H3K4 methyltransferase activity by its core components.

Dou Y, Milne TA, Ruthenburg AJ, Lee S, Lee JW, Verdine GL, Allis CD, Roeder RG.

Nat Struct Mol Biol. 2006 Aug;13(8):713-9. Epub 2006 Jul 30.

PMID:
16878130
40.

A PHD finger of NURF couples histone H3 lysine 4 trimethylation with chromatin remodelling.

Wysocka J, Swigut T, Xiao H, Milne TA, Kwon SY, Landry J, Kauer M, Tackett AJ, Chait BT, Badenhorst P, Wu C, Allis CD.

Nature. 2006 Jul 6;442(7098):86-90. Epub 2006 May 21.

PMID:
16728976
41.
42.

MLL associates specifically with a subset of transcriptionally active target genes.

Milne TA, Dou Y, Martin ME, Brock HW, Roeder RG, Hess JL.

Proc Natl Acad Sci U S A. 2005 Oct 11;102(41):14765-70. Epub 2005 Sep 30.

43.

Taking LSD 1 to a new high.

Wysocka J, Milne TA, Allis CD.

Cell. 2005 Sep 9;122(5):654-8. Review.

44.

Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF.

Dou Y, Milne TA, Tackett AJ, Smith ER, Fukuda A, Wysocka J, Allis CD, Chait BT, Hess JL, Roeder RG.

Cell. 2005 Jun 17;121(6):873-85.

45.

WDR5 associates with histone H3 methylated at K4 and is essential for H3 K4 methylation and vertebrate development.

Wysocka J, Swigut T, Milne TA, Dou Y, Zhang X, Burlingame AL, Roeder RG, Brivanlou AH, Allis CD.

Cell. 2005 Jun 17;121(6):859-72.

46.

Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors.

Milne TA, Hughes CM, Lloyd R, Yang Z, Rozenblatt-Rosen O, Dou Y, Schnepp RW, Krankel C, Livolsi VA, Gibbs D, Hua X, Roeder RG, Meyerson M, Hess JL.

Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):749-54. Epub 2005 Jan 7.

47.

Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus.

Hughes CM, Rozenblatt-Rosen O, Milne TA, Copeland TD, Levine SS, Lee JC, Hayes DN, Shanmugam KS, Bhattacharjee A, Biondi CA, Kay GF, Hayward NK, Hess JL, Meyerson M.

Mol Cell. 2004 Feb 27;13(4):587-97.

48.

Dimerization of MLL fusion proteins immortalizes hematopoietic cells.

Martin ME, Milne TA, Bloyer S, Galoian K, Shen W, Gibbs D, Brock HW, Slany R, Hess JL.

Cancer Cell. 2003 Sep;4(3):197-207.

49.

MLL targets SET domain methyltransferase activity to Hox gene promoters.

Milne TA, Briggs SD, Brock HW, Martin ME, Gibbs D, Allis CD, Hess JL.

Mol Cell. 2002 Nov;10(5):1107-17.

50.

Tantalus, a novel ASX-interacting protein with tissue-specific functions.

Dietrich BH, Moore J, Kyba M, dosSantos G, McCloskey F, Milne TA, Brock HW, Krause HM.

Dev Biol. 2001 Jun 15;234(2):441-53.

Supplemental Content

Loading ...
Support Center